CR20150637A - Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral - Google Patents
Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteralInfo
- Publication number
- CR20150637A CR20150637A CR20150637A CR20150637A CR20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A CR 20150637 A CR20150637 A CR 20150637A
- Authority
- CR
- Costa Rica
- Prior art keywords
- parenteral administration
- protein aggregation
- miopatic
- treatment
- neurodegenerative diseases
- Prior art date
Links
- 238000007911 parenteral administration Methods 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000004845 protein aggregation Effects 0.000 title 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000004849 abnormal protein aggregation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361820278P | 2013-05-07 | 2013-05-07 | |
| PCT/IL2014/050411 WO2014181333A2 (en) | 2013-05-07 | 2014-05-07 | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150637A true CR20150637A (es) | 2016-04-05 |
Family
ID=51022384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150637A CR20150637A (es) | 2013-05-07 | 2015-12-04 | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10493023B2 (enExample) |
| EP (2) | EP2994145B1 (enExample) |
| JP (5) | JP6837835B2 (enExample) |
| KR (1) | KR20160009617A (enExample) |
| AU (5) | AU2014264228A1 (enExample) |
| CA (2) | CA2911399C (enExample) |
| CR (1) | CR20150637A (enExample) |
| EA (1) | EA201501054A1 (enExample) |
| IL (1) | IL241757B (enExample) |
| MD (1) | MD20150120A2 (enExample) |
| MX (1) | MX2015015355A (enExample) |
| PE (1) | PE20160012A1 (enExample) |
| SG (1) | SG11201509030TA (enExample) |
| WO (1) | WO2014181333A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220288096A1 (en) * | 2013-05-07 | 2022-09-15 | Seelos Therapeutics, Inc. | Compositions and methods for treating an aggregation disease or disorder |
| US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| EA201501054A1 (ru) | 2013-05-07 | 2016-04-29 | Био Бласт Фарма Лтд. | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы |
| US10736909B2 (en) | 2016-02-08 | 2020-08-11 | Junaxo, Inc. | Use of trehalose for treatment of neurological diseases |
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| EA202090510A1 (ru) | 2017-08-14 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Способ лечения бокового амиотрофического склероза придопидином |
| WO2019143685A1 (en) | 2018-01-16 | 2019-07-25 | Women & Infants Hospital Of Rhode Island | Methods and compositions for treating pre-eclampsia |
| WO2021067243A1 (en) | 2019-10-01 | 2021-04-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
| JP7701931B2 (ja) * | 2020-02-13 | 2025-07-02 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法 |
| WO2022013940A1 (ja) | 2020-07-14 | 2022-01-20 | オリンパス株式会社 | 嚥下検査用システム、嚥下検査方法及び嚥下検査プログラムを記録した記録媒体 |
| CN116966192A (zh) * | 2022-09-26 | 2023-10-31 | 西安文理学院 | 海藻糖在制备sca3疾病治疗药物中的应用 |
| WO2024118797A1 (en) * | 2022-11-30 | 2024-06-06 | Seelos Therapeutics, Inc. | Trehalose for treating huntington's disease |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3782404A (en) | 1972-06-14 | 1974-01-01 | Commercial Shearing | Adjustable, metered, directional flow control arrangements |
| JPS4950521U (enExample) | 1972-08-14 | 1974-05-02 | ||
| JPS516109B2 (enExample) | 1972-12-28 | 1976-02-25 | ||
| JPS557829Y2 (enExample) | 1974-07-01 | 1980-02-21 | ||
| JPS516109A (en) | 1974-07-05 | 1976-01-19 | Toshiba Tungaloy Co Ltd | Aruminaatankachitan chitsukachitankeishoketsugokin |
| WO1997024129A1 (en) | 1995-12-27 | 1997-07-10 | Rohto Pharmaceutical Co., Ltd. | Pharmaceutical composition containing trehalose |
| JP4033510B2 (ja) | 1995-12-27 | 2008-01-16 | ロート製薬株式会社 | トレハロースを含有する眼科用医薬組成物 |
| JP3455633B2 (ja) | 1996-06-28 | 2003-10-14 | 味の素ファルマ株式会社 | 潰瘍性大腸炎の予防又は治療剤 |
| US6440446B1 (en) | 1998-04-22 | 2002-08-27 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Agent for anti-osteoporosis |
| US6602865B1 (en) | 1998-11-16 | 2003-08-05 | Ivax Drug Research Institute, Ltd. | Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds |
| JP2001302517A (ja) * | 2000-04-24 | 2001-10-31 | Tokyo Univ Of Pharmacy & Life Science | 脳浮腫の予防治療薬 |
| CA2355814C (en) | 2000-09-14 | 2010-06-29 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Pharmaceutical composition for ophthalmic use |
| JP4754066B2 (ja) | 2000-12-22 | 2011-08-24 | 株式会社林原生物化学研究所 | 抗関節障害剤 |
| JP4255101B2 (ja) * | 2002-03-15 | 2009-04-15 | 独立行政法人理化学研究所 | 神経変性疾患の治療薬 |
| US20050053666A1 (en) * | 2002-12-31 | 2005-03-10 | Stelios Tzannis | Antibody-containing particles and compositions |
| EP1600143B1 (en) | 2003-02-13 | 2019-07-10 | Hayashibara Co., Ltd. | SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| US20050100637A1 (en) * | 2003-11-12 | 2005-05-12 | Robert Murray | Carbohydrate and electrolyte replacement composition |
| US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| EP1888095A4 (en) | 2005-05-13 | 2009-08-26 | Whitehead Biomedical Inst | MODULATORS OF ALPHA-SYNUCLEIN INDUCED TOXICITY |
| MY142987A (en) | 2005-06-08 | 2011-02-14 | Hayashibara Biochem Lab | Solution for tissue adhesion prevention and method for tissue adhesion prevention |
| JP2006342108A (ja) * | 2005-06-09 | 2006-12-21 | Mitsubishi Chemicals Corp | アミロスフェロイドにより発生する疾患の予防治療剤 |
| CN102266274B (zh) | 2005-08-11 | 2016-05-18 | 株式会社林原 | 胶原产生增强剂及其用途 |
| EP1958612B1 (en) | 2005-11-30 | 2014-07-02 | The Nisshin OilliO Group, Ltd. | Trehalose fatty acid ester composition |
| JP4950521B2 (ja) | 2006-03-08 | 2012-06-13 | 公益財団法人野口研究所 | トレハロース誘導体とその製造法 |
| WO2007111214A1 (ja) | 2006-03-27 | 2007-10-04 | Otsuka Chemical Co., Ltd. | トレハロース化合物および該化合物を含有する医薬 |
| CN100571707C (zh) | 2006-07-24 | 2009-12-23 | 凌沛学 | 含有海藻糖的关节腔内注射给药制剂 |
| JP5258582B2 (ja) | 2007-01-31 | 2013-08-07 | 株式会社糖鎖工学研究所 | トレハロース化合物、その製造方法、及び該化合物を含有する免疫賦活剤 |
| WO2008102563A1 (ja) | 2007-02-23 | 2008-08-28 | Next21 K.K. | 血管攣縮の治療剤又は予防剤 |
| TW200848063A (en) | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| EP2214714A4 (en) * | 2007-10-31 | 2011-01-12 | Diffusion Pharmaceuticals Llc | NEW CLASS OF THERAPEUTIC AGENTS THAT ENHANCE SMALL MOLECULE DELIVERY |
| JP2009249292A (ja) * | 2008-04-01 | 2009-10-29 | Toray Ind Inc | ポリリン酸を安定化剤とするエリスロポエチン溶液製剤 |
| WO2010008860A1 (en) * | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| KR101021078B1 (ko) | 2008-07-22 | 2011-03-14 | 포항공과대학교 산학협력단 | 이노시톨 또는 트리할로스 유도체 및 이를 함유하는 퇴행성뇌신경계 질환 치료용 약학 조성물 |
| EP2567963A1 (en) | 2008-10-31 | 2013-03-13 | Otsuka Chemical Co., Ltd. | Trehalose compound, method for producing same, and pharmaceutical product containing the compound |
| CN102438652B (zh) * | 2008-11-12 | 2014-08-13 | 米迪缪尼有限公司 | 抗体制剂 |
| CA3039907C (en) | 2008-12-10 | 2022-12-13 | Wista Laboratories Ltd. | 3,6-disubstituted xanthylium salts |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| JP5869882B2 (ja) | 2010-03-05 | 2016-02-24 | 株式会社林原 | インスリン抵抗性の予防及び／又は改善剤 |
| PL2593131T3 (pl) | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Sposoby i kompozycje do dostarczania sulfatazy-2-iduronianiu do oun |
| CN101914118B (zh) | 2010-08-06 | 2012-07-04 | 山东大学 | 海藻糖衍生物及其制备方法与应用 |
| US20140066439A1 (en) * | 2010-11-10 | 2014-03-06 | Katholieke Universiteit Leuen, K.U.Leuven R&D | Osteoclast activity |
| US9186356B2 (en) | 2011-01-08 | 2015-11-17 | Academia Sinica | Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) |
| EP2721151B1 (en) | 2011-06-20 | 2017-12-06 | Mount Sinai School Of Medicine | Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders |
| US8623839B2 (en) * | 2011-06-30 | 2014-01-07 | Depuy Mitek, Llc | Compositions and methods for stabilized polysaccharide formulations |
| US20130310467A1 (en) | 2012-03-06 | 2013-11-21 | The Nisshin Oillio Group, Ltd. | Trehalose fatty acid ester composition |
| JP5432322B2 (ja) | 2012-05-08 | 2014-03-05 | 株式会社大塚製薬工場 | トレハロース含有肺塞栓形成予防用哺乳動物細胞懸濁液 |
| US20130312784A1 (en) | 2012-05-24 | 2013-11-28 | For Your Ease Only, Inc. | Cosmetic organizer |
| US20140032304A1 (en) | 2012-07-27 | 2014-01-30 | Google Inc. | Determining a correlation between presentation of a content item and a transaction by a user at a point of sale terminal |
| JP2014139160A (ja) | 2012-12-21 | 2014-07-31 | Masaaki Hayashibara | 脳機能改善剤及び脳機能改善用食品 |
| US20220288096A1 (en) | 2013-05-07 | 2022-09-15 | Seelos Therapeutics, Inc. | Compositions and methods for treating an aggregation disease or disorder |
| EA201501054A1 (ru) | 2013-05-07 | 2016-04-29 | Био Бласт Фарма Лтд. | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы |
| US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
| JP6130224B2 (ja) | 2013-05-27 | 2017-05-17 | 公益財団法人微生物化学研究会 | 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物 |
| TWI507197B (zh) | 2013-07-17 | 2015-11-11 | Univ Nat Taiwan Normal | 醫藥組成物於製備不正常多麩醯胺聚集類疾病之藥物上之用途 |
| WO2015009961A1 (en) | 2013-07-19 | 2015-01-22 | Armagen Technologies, Inc. | Compositions and methods related to structures that cross the blood brain barrier |
| US20170354666A1 (en) | 2014-11-19 | 2017-12-14 | Rush University Medical Center | Compositions and methods for treating lysosomal disorders |
| US20160303150A1 (en) | 2015-04-16 | 2016-10-20 | BioBlast Pharma Ltd. | Deuterated trehalose formulations and uses thereof |
| WO2017136533A1 (en) | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses |
| US10512656B2 (en) | 2016-04-21 | 2019-12-24 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
| WO2021067243A1 (en) | 2019-10-01 | 2021-04-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
-
2014
- 2014-05-07 EA EA201501054A patent/EA201501054A1/ru unknown
- 2014-05-07 EP EP14733380.1A patent/EP2994145B1/en active Active
- 2014-05-07 AU AU2014264228A patent/AU2014264228A1/en not_active Abandoned
- 2014-05-07 KR KR1020157034700A patent/KR20160009617A/ko not_active Withdrawn
- 2014-05-07 EP EP22216238.0A patent/EP4218769A3/en active Pending
- 2014-05-07 WO PCT/IL2014/050411 patent/WO2014181333A2/en not_active Ceased
- 2014-05-07 MX MX2015015355A patent/MX2015015355A/es unknown
- 2014-05-07 JP JP2016512480A patent/JP6837835B2/ja active Active
- 2014-05-07 PE PE2015002367A patent/PE20160012A1/es not_active Application Discontinuation
- 2014-05-07 CA CA2911399A patent/CA2911399C/en active Active
- 2014-05-07 US US14/889,727 patent/US10493023B2/en active Active
- 2014-05-07 CA CA3239805A patent/CA3239805A1/en active Pending
- 2014-05-07 SG SG11201509030TA patent/SG11201509030TA/en unknown
- 2014-05-07 MD MDA20150120A patent/MD20150120A2/ro not_active Application Discontinuation
-
2015
- 2015-09-21 IL IL241757A patent/IL241757B/en active IP Right Grant
- 2015-12-04 CR CR20150637A patent/CR20150637A/es unknown
-
2019
- 2019-04-11 JP JP2019075517A patent/JP2019142907A/ja active Pending
- 2019-06-26 AU AU2019204513A patent/AU2019204513B2/en active Active
- 2019-07-02 US US16/460,046 patent/US10869831B2/en active Active
-
2020
- 2020-11-26 AU AU2020277197A patent/AU2020277197A1/en not_active Abandoned
-
2021
- 2021-06-08 JP JP2021095562A patent/JP2021152032A/ja active Pending
- 2021-06-23 US US17/355,607 patent/US20220117883A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002536A patent/JP2023040211A/ja active Pending
- 2023-01-20 AU AU2023200303A patent/AU2023200303A1/en not_active Abandoned
- 2023-04-05 US US18/131,161 patent/US12239733B2/en active Active
-
2025
- 2025-03-07 JP JP2025036306A patent/JP2025087858A/ja active Pending
- 2025-03-13 AU AU2025201824A patent/AU2025201824A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150637A (es) | Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| BR112016007467A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CL2015002485A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| CR20150480A (es) | Composición farmacéutica de clorhidrato de s-cetamina | |
| MX366317B (es) | Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias. | |
| CR20150481A (es) | Composición farmacéutica de clorhidrato de s-ketamina | |
| IL263516B (en) | A dosage form for vaporization and smoking | |
| MX2017011375A (es) | Método para tratar un tumor cerebral. | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| PE20151526A1 (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod | |
| MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
| MX2018012230A (es) | Métodos para tratar enfermedades oculares. | |
| MX2017005064A (es) | Metodos para tratar afecciones oculares. | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| TR201310724A2 (tr) | Linagliptinin farmasotik formulasyonları. | |
| WO2014107737A3 (en) | Local delivery of il-17 inhibitors for treating ocular disease | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. |